The Journal of Clinical Endocrinology & Metabolism · 2005 · 105 citations · 20 references
MedicineEndocrinologyPediatric EndocrinologyPediatric PharmacotherapyReproductive EndocrinologyBone Health In AdolescencePubertal DevelopmentPrecocious Puberty EvaluationPubertal Bone DevelopmentPubertal Growth PredictionPubertal Skeletal Growth
We evaluated the effect of leuprorelin treatment on adult height (AH) and followed recovery of reproductive function in 63 girls and 13 boys with central precocious puberty (CPP). Mean treatment durations were 3.8 +/- 2.0 and 4.1 +/- 2.5 yr, and posttreatment follow-up durations were 3.5 +/- 1.3 and 2.6 +/- 1.1 yr for girls and boys, respectively. AH was 154.5 +/- 5.7 cm for girls, and 89.5% of girls reached AH within their target height range. For boys, AH was 163.2 +/- 13.0 cm, and 90.9% reached target height range. It appeared that the Bayley-Pinneau method, modified for Japanese children, using a table for advanced bone age (BA), overestimated AH in CPP; and this method, using a table for average BA and projected height for BA, was suitable for prediction of AH in CPP. Menarche or remenarche occurred in 96.8% of girls at the age of 13.1 +/- 1.5 yr. Of 11 girls who contributed urine samples, all seven idiopathic and two organic cases were considered to have ovulation. Serum testosterone levels reached normal adult level in all boys. In conclusion, long-term leuprorelin treatment for children with CPP improved AH and had no adverse effects on recovery of reproductive function.
20
W F Crowley, F. COMITF, Wylie Vale et al. · The Journal of Clinical Endocrinology & Metabolism · 1981 · 274 citations · Full text
Karen O. Klein, Kevin M. Barnes, Janet V. Jones et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 205 citations
Medicine, Endocrinology, Pediatrics +13
Sabine Heger, Carl‐Joachim Partsch, Wolfgang G. Sippell · The Journal of Clinical Endocrinology & Metabolism · 1999 · 201 citations · Full text